Available online on 15.1.2020 at <http://ujpr.org>
Universal Journal of Pharmaceutical Research
 An International Peer Reviewed Journal

Open access to Pharmaceutical research
 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial Share Alike 4.0 License which permits unrestricted non commercial use, provided the original work is properly cited

Volume 4, Issue 6, 2019

Open Access

RESEARCH ARTICLE

IN VITRO-IN VIVO BIO-EQUIVALENCE CORRELATION STUDY OF ATENOLOL, AND ITS BRANDS OF IMMEDIATE RELEASE TABLET UNDER BIO-WAIVER CONDITIONS

Ahmed EM¹, Ibrahim ME¹, Magbool FF²

¹College of Pharmacy, Department of Pharmaceutical Chemistry, Ribat National University, Khartoum, Sudan.

²Department of Pharmaceutical Chemistry, Omdurman Islamic University, Sudan.

ABSTRACT

Objective: The aim of present study is to examine the *in vitro-in vivo* correlation (IVIVC) of immediate release product. Atenolol 100mg and its brands of immediate release dosage forms. Atenolol is clearly classified into BCS class III, and could be evaluated under bio waiver conditions.

Methods: The *in vitro* parameters employed were hardness, weight uniformity, friability, disintegration time, absolute drug content, dissolution rate (in 0.1 N Hydrochloric acid, phosphate buffer and acetate buffer at 37°C), and dissolution efficiencies were also analyzed. The *in-vitro* dissolution study was performed on the brands, according to FDA, USP dissolution profile in three different PH (1.2), (4.5), and (6.8) at 37°C, using the USP apparatus II. A non linear relation was established which is typical for immediate release formulation, of class III.

Results: All Atenolol brands released about 90% drug in PH (6.8), where about 87% in PH (4.5), reference drug released about 91% and test drug released about 87% in pH (1.2). Dissolution efficiency of the entire brands differed by less than 10% from the innovator brand. According to MINITAM 14 statistical program, there was significant relationship between *in vitro* and *in vivo* data of reference Atenolol product.

Conclusion: By applying level A *in vitro-in vivo* correlation, study concluded that there is no linear correlation between percent of drug released and percent of drug absorbed, this may be due to uncontrollable permeability rate for class three Atenolol.

Keywords: Bioavailability, bioequivalence, biopharmaceutical classification system, Bio-waiver correlation.

Article Info: Received 20 September 2019; Revised 16 December; Accepted 7 January, Available online 15 January 2020

Cite this article-

Ahmed EM, Ibrahim ME, Magbool FF. *In vitro-in vivo* bio-equivalence correlation study of atenolol, and its brands of immediate release tablet under bio-waiver conditions. Universal Journal of Pharmaceutical Research 2019; 4(6):25-29.

DOI:<https://doi.org/10.22270/ujpr.v4i6.332>

Address for Correspondence:

Fatehalrahman F. Magbool, Department of Pharmaceutical Chemistry, Omdurman Islamic University, Sudan. Tel: +966-582158608, E-mail: fmagbool@yahoo.com

INTRODUCTION

Bio-equivalence is defined as the absence of a significant difference in the rate and extent to which the active ingredient or active moiety in pharmaceutical equivalents or pharmaceutical alternatives becomes available at the site of drug action when administered at the same molar dose under similar conditions in an appropriately designed study. If two medicines are bioequivalent there is no clinically significant difference in their bioavailability¹. Development and optimization of formulation is an integral part of manufacturing and marketing of any therapeutic agent which is indeed a time consuming and costly process. Optimization process may require alteration in formulation composition, manufacturing process, equipment and batch sizes. If these types of changes are applied to a formulation, studies in human healthy

volunteers may be required to prove that the new formulation is bioequivalent with the old one². Certainly, implementation of these requirements not only halts the marketing of the new formulation but also increases the cost of the optimization processes. It would be, desirable, therefore, to develop *in vitro* tests that reflect bioavailability data. A regulatory guidance for both immediate- and modified-release dosage forms has been, therefore, developed by the FDA to minimize the need for bioavailability studies as part of the formulation design and optimization³. IVIVC can be used in the development of new pharmaceuticals to reduce the number of human studies during the formulation development.

Atenolol is a selective β_1 receptor antagonist, a drug belonging to the group of beta blockers (sometimes written β -blockers), a class of drugs used primarily in

cardiovascular diseases. Introduced in 1976, atenolol was developed as a replacement for propranolol in the treatment of hypertension. It works by slowing down the heart and reducing its workload⁴.

MATERIALS AND METHODS

ATN reference standard USP, Mfg. August 2013, Exp. July 2018, and three different brands of ATN tablets 50 mg obtained from local market, DW and Methanol 99.8% (Sharlau, Spain).

Uniformity of weight test

Twenty randomly selected tablets were weighed. The average weights were determined. The tablets were weighed individually and the percentage of deviation of its weight from the average weight was determined for each tablet⁴.

Hardness test

The hardness of 10 tablets randomly selected from each batch was determined on an automatic tablet hardness tester. The crushing strength of uncoated tablets is accepted within 4-8 kg/cm².

Friability test

20 tablets previously freed of dust were weighed together before transferring to a friabilator set to run for 4 min at 25 rpm. Thereafter they were removed, dusted and reweighed:

$$\% \text{ Friability} = \frac{W_i - W_f}{W_i} \times 100$$

Where, W_i is the initial weight and

W_f is the final weight of the tablets.

Disintegration time test

According to official monograph determination of disintegration time for uncoated tablets was adopted using a disintegrating apparatus and the medium was distilled water at $37 \pm 1^\circ\text{C}$. Six tablets were used for the determination. Accepted range for the uncoated tablet up to 30 minutes⁵.

Absolute drug content

Five pre-weighed tablets were crushed; the equivalent weight of a tablet was weighed out and dissolved in 100ml volumetric flask and filtered. The absorbance reading was determined using UV-visible spectrophotometer at 273 nm⁴.

In vitro dissolution test

Volume of 900 ml of each buffer was employed. Dissolution testing was performed using Tablet Dissolution Tester (USP Apparatus 2) at 75 rpm for class III test and reference products, temperature will be adjusted to $37 \pm 0.5^\circ\text{C}$. Twelve dosage units of each product test and reference were evaluated in the three media. Sample aliquots of 10 ml were taken manually with syringes. Samples were withdrawn at specified time intervals (10, 15, 30, 45, and 60 min) and replaced with 10 ml of appropriate medium. Withdrawn samples were filtered using 0.45- μm Millipore Filters, then 5 ml taken after filtration by volumetric pipette (3ml taken when use HCL buffer solution, and 1ml taken in case of acetate and phosphate buffer, and diluted to 50 ml). A UV-visible spectrophotometer was used to analyze dissolved drug in dissolution testing. Scanning of wavelength done in each buffer, and spectrum recorded between 200-800nm, and percentage of drug dissolved calculated⁶.

Buffers preparation

Simulated gastric fluid (SGF), simulated intestinal fluid (SIF), and acetate buffer PH (4.5) were prepared according to instructions in USP test solution. All media were prepared without enzymes, as follows:

Simulated Gastric Fluid (SGF) PH (1.2)

To prepare hydrochloric acid 0.1N, 8.5 ml was taken from concentrated HCL (37%) and volume completed to 1000 ml by distilled water⁷.

Simulated Intestinal Fluid (SIF) pH (6.8)

Potassium phosphate monobasic KH_2PO_4 0.2 M was prepared by dissolving 27.22 g in water, and volume diluted to 1000 ml by distilled water. Then sodium hydroxide 0.2 M prepared by dissolving 8g in water and volume diluted to 1000 ml by distilled water. 250 ml from Potassium phosphate monobasic KH_2PO_4 0.2 M was placed into 200 ml volumetric flask, also 112 ml taken from sodium hydroxide 0.2M and volume completed to 1000 ml with distilled water⁷.

Acetate buffer pH (4.5)

Firstly acetic acid 0.2N was prepared from concentrated acetic acid 99.93%. Measured amount of 116 ml was taken and diluted with distilled water. Then 2.99 g of sodium acetate ($\text{NaC}_2\text{H}_3\text{O}_2$) taken, and placed in 1000 ml volumetric flask, 14ml from acetic acid was added and volume completed to 1000 ml by distilled water⁸.

Preparation of standard stock solutions

Standard stock solutions of Atenolol in HCL, phosphate and acetate buffers were prepared by dissolving 100 mg of standard in 100 ml volumetric flask using acetate and phosphate buffers as solvents to give concentration of 1000 $\mu\text{g/ml}$, 5 ml diluted to 100 ml volumetric flask (50 $\mu\text{g/ml}$), using 50 ml volumetric flask to give serial concentration of standard curve⁸.

Statistical analysis

All dissolution data evaluated using Excel spread sheet, and the results will be plotted for each brand. Average of % content of active pharmaceutical ingredient (API) dissolved in each media of 12 tablets will be taken and a plot of % of (API) dissolved against time will be drawn to represent the dissolution profile. The dissolution profile for local brand will be compared to that of the reference drug⁹.

If they are similar the similarity factor, f_2 equal to or more than 50. This means that they are equivalent, if it's less than 50 they are not equivalent.

$$f_1 = \{ [3t = 1n / Rt - Tt] / [3t = 1n Rt] \} C$$

$$f_2 = 50 C \log \{ [1 + (1/n) 3t = 1n (Rt - Tt)^2] - 0.5C 100 \}$$

Similarity factor f_2 has been adopted by FDA and the European Agency for the Evaluation of Medicinal Products (EMA) by the Committee for Proprietary Medicinal Products (CPMP) as a criterion to compare the similarity of two or more dissolution profiles. Similarity factor f_2 is included by the Centre for Drug Evaluation and Research (CDER) in their guidelines such as guidance on dissolution testing of immediate release solid oral dosage forms (FDA, 1997) and guidance on waiver of *in-vivo* bioavailability and bioequivalence studies for immediate release solid oral dosage forms based on a biopharmaceutics classification system (FDA, 2000).

The area under the dissolution-time curve method was used in calculating the dissolution efficiency (DE), and this was calculated at 30 min. The higher the dissolution efficiency (DE) is, the better the release efficiency of the tablets' active ingredient, according to equation:

$$DE = \left\{ \left[\int_{t_i}^{t_f} \% D_t \cdot dt \right] / [\% D_{max} \cdot (t_f - t_i)] \right\} \cdot 100 = \left[AUC_{0-T} / \% D_{max} \cdot T \right] \cdot 100$$

Where %D is the percentage dissolved at time t, % D (max) is the maximum dissolved at the final time T, and AUC (0-T) is the area under the curve from zero to time T^{10,11}.

Correlation calculation was carried out using MINITAB14 specific statistical program.

In vitro-In vivo relationship determination of level A correlation.

In vivo percent absorbed of reference product was calculated by following equation:

$$\frac{A_t}{A_0} = \frac{C_t + K_{el} \cdot AUC_0^t}{K_{el} \cdot AUC_0^\infty}$$

Where, $\frac{A_t}{A_0}$ denotes the fraction of drug absorbed at time t, C_t is the plasma drug concentration at time t, K_{el} is elimination rate constant, AUC_0-t and $AUC_0-\infty$ are the area under the plasma concentration–time profile curve at time t and ∞ respectively. Then the values of percent of drug released were plotted against the percent of drug absorbed for reference products of Atenolol using MINITAB14 analysis program to find out the relationship between data (correlation).

RESULTS AND DISCUSSION

A summary of the results of weight uniformity, hardness, friability, disintegration and assay are shown in Table 2. Weight uniformity may serve as a pointer to amount of the active pharmaceutical ingredient (API) contained in the formulation.

Table 1: Weight uniformity of atenolol tablets.

Number of tablets	Deviation (%)	Average weight of tablets
Minimum 18	±10.0	Less than 80 mg
Maximum 20	±20.0	
Minimum 18	±7.5	80mg to 250mg
Maximum 20	±15.0	
Minimum 18	±5.0	More than 250mg
Maximum 20	±10.0	

All the brands complied with the compendial specification for weight uniformity. Hardness is referred to as non-compendial test. The hardness or crushing strength assesses the ability of dosage form to withstand handling without fracturing or chipping. It can also influence other parameters such as friability and disintegration. Hence, the dosage forms of all brands were satisfactory for hardness⁷. Friability test is

used to evaluate the tablets resistance to abrasion. Friability is now included in the United States Pharmacopeia (USP, 1995) as a compendia test. The compendial specification for friability is less or equal to 1%. Friability for all brands of Atenolol was below 1%. Disintegration is the process of breaking of tablets in the liquid. Disintegration is a crucial step for immediate release dosage forms because the rate of disintegration affects the dissolution and subsequently the therapeutic efficacy of the medicine. A drug will be released rapidly as the dosage forms disintegrate. British Pharmacopeia specifies that uncoated tablets should disintegrate within 15 min and film coated tablet disintegrate within 30 min while USP specification for disintegration is 30 min for both uncoated and film coated tablets. All the brands were complied with both BP and USP specifications for disintegration as maximum disintegration time. Potency is the average amount of the active ingredient present per tablet. All the brands complied both BP and USP specification, as USP specification is that the content of active ingredient should not be less than 90% and not more than 110% while BP specifies that the content should not be less than 95% and not more than 105%. The results of dissolution studies are graphically represented in the Figure 1, Figure 2 and Figure 3. All dissolution data are based on the actual drug content of the test dosage form as calculated from the assay results. All Atenolol brands released about 90% drug in PH (6.8), where about 87% in PH (4.5), reference drug released about 91% and test drug released about 87% in pH (1.2). To compare the dissolution profiles of the brands, a model independent approach of difference factor f1 and similarity factor f2 were employed. Difference factor f1 is the percentage difference between two curves at each point and is a measurement of the relative error between the two curves. The similarity factor (f2) is a logarithmic reciprocal square root transformation of the sum of squared error and is a measurement of the similarity in the percent (%) dissolution between two curves. Two dissolution profiles to be considered similar and bioequivalent, f1 should be between 0 and 15 while f2 should be between 50 and 100 (FDA, 1997). All the values for f2 and f1 shown in Table 3 for atenolol, all brands f2 values were more than 50 and f1 values were less than 15. It means that all brands were equivalent with the innovator brand. *In-vitro* AUC in three PH (1.2),(4.5),(6.8) for class III product, there was large difference between *in-vitro* AUC and *in-vivo* AUC, the *in-vivo* AUC is too small due to the lower permeability for this class of drug products, which will affect their AUC. The reference and the test product can said to be equivalent if the difference between their dissolution efficiencies is within appropriate limits (±10%, which is often used).

Table 2: Quality control test results of atenolol brands.

Brands	Hardness (kg/cm)	Weight variation (RSD)	Disintegration Time(min)	Friability %	Assay %
Sample (A)	6.7	0.027	8:7	0.01158	99.88
Sample (B)	5.9	0.185	6:6	0.0184	103

Table 3: F1 and F2 values for Atenolol.

Samples	1.2		4.5		6.8	
	F1	F2	F1	F2	F1	F2
Sample (B)	3	71	1	92	2	87

Figure 1: Dissolution profile of Atenolol in pH (1.2).

Dissolution efficiency of the entire brands differed by less than 10% from the innovator brand. So, we can say that all the brands are pharmaceutically equivalent with the innovator brand⁶.

Figure 2: Dissolution profile of Atenolol in pH (4.5).

As IVIVC is a predictive mathematical model describing the relationship between variables (an *in vitro* property of a dosage form and a relevant *in vivo* response). According to MINITAM 14 statistical program, there was significant relationship between *in vitro* and *in vivo* data of reference Atenolol product, Correlation and distribution of data with correlation coefficient ($r=0.798, 0.815, 0.967$), non linear

Table 4: Dissolution efficiency for Atenolol brands.

Brands	1.2		4.5		6.8	
	AUC	Difference with reference	AUC	Difference with reference	AUC	Difference with reference
Brand (A)	348.83	-	357.68	-	364.69	-
Brand (B)	358.05	-9.22	355.93	1.75	359.43	-5.26

Figure 3: Dissolution profile of Atenolol in pH (6.8).

relationship with p -value (>0.05)=(0.106, 0.93, 0.009), there is no out lines, no lake of fits at p -values=0.106, 0.040, 0.056 (>0.05) for the three pH (1.2,4.5,6.8) respectively⁸. Estimating the uncertainty in predicted correlation between *vitro* and *vivo* data. The interval is represented by the curved lines on either side of the regression line and gives an indication of the range within which the 'true' line might lie. Note that the confidence interval is narrowest near the center (the point x, y) and less certain near the extremes. By applying analysis of variance (ANOVA) for the dissolution data using MINITAB 14 we concluded that the test products are bioequivalent to reference products of Atenolol and could be interchangeable.

CONCLUSION

The bio waiver study has emphasized that pharmaceutical equivalence indicate that product have same drug molecule with approximately same pattern of dissolution release profile. By making fine turning in bioequivalent study we can reduce the time, cost, avoid Ethical, Ethnical consideration by unnecessary exposure of healthy subjects to medicines and finally to market the quality generic drug product. By applying level A *in vitro-in vivo* correlation, study concluded that there is no linear correlation between percent of drug released and percent of drug absorbed, this may be due to uncontrollable permeability rate for class three Atenolol. Atenolol are immediate release formulations. As dissolution is not a rate-limiting step in IR products, the fraction of drug absorbed against the fraction of drug released profile would be non-linear type which was obtained in present study. So it may be concluded that the *in vitro-in vivo* correlation is well established and justified for both reference formulations by level A correlation.

Figure 4: Atenolol correlation at pH (1.2).

Table 5: Relative dissolution efficiency of sample (B).

PH	1.2	4.5	6.8
%	102.64	99.51	98.56

Figure 5: Atenolol correlation at pH (4.5).

Figure 6: Atenolol correlation at pH (6.8).

By applying analysis of variance (ANOVA) for the dissolution data using MINITAB 14 we concluded that the test products are bioequivalent to reference products of Atenolol and could be interchangeable.

ACKNOWLEDGEMENT

The authors are thankful to wish to Azal Industries, Khartoum, Sudan, for providing the gift sample of Atenolol (standard).

AUTHOR'S CONTRIBUTION

The manuscript was carried out, written, and approved in collaboration with all authors.

CONFLICT OF INTEREST

No conflict of interest associated with this work.

REFERENCES

1. El-Gindy A, Emara S, Mostafa A. HPLC and chemometric assisted spectrophotometry method for simultaneous determination of atenolol, amiloride hydrochloride and chlorthalidone. *IL Pharmaco* 2005; 60:269-278. <https://doi.org/10.1016/j.farmac.2004.11.013>
2. Bevinakatti LH, Banerji A, Lipase A. catalysis in organic solvents. application to the synthesis of (R)-and (S)-Atenolol. *J Org Chem* 1992; 57(22): 6003-6005. <https://doi.org/10.1021/jo00048a040>
3. Agon P, Goethals P, Van Haver D, Kaufman JM. Permeability of the blood-brain barrier for atenolol studied by positron emission tomography. *J Pharm Pharmacol* 1991; 43(8): 597-600. <https://doi.org/10.1111/j.2042-7158.1991.tb03545.x>
4. Kudige N, Prashanth, Kanakapura B, Anal J. Sensitive spectrophotometric determination of atenolol in pharmaceutical formulations using bromate-bromide as an eco-friendly brominating agent methods chem. *J Analyt Meth Chem* 2012; 20.<https://doi.org/10.1155/2012/810156>
5. Lalitha KV, Kiranjyoth R, Pama B. UV spectrophotometric method development and validation for the determination of atenolol and losartan potassium by Q-analysis. *Int Bulletin Drug Res* 2013; 3(4): 54-62. <https://doi.org/10.4103/2229-4708.90364>
6. BP2009 formulated preparation: specific monograph, 3, Atenolol tab. <https://doi.org/10.1016/j.hrthm.2019.01.024>
7. International Conference on Harmonization of Technical requirements for Registration of Pharmaceuticals for Human, ICH Harmonized Tripartite Guideline, and Validation of Analytical procedure: Text and Methodology Q2 (R1).Current step version, Parent Guideline Dated 27 October 1994, (Complementary Guideline on Methodology dated 6 November 1996 incorporated in November 2005). <https://doi.org/10.4103/0976-500X.162004>
8. Mcpolin, Oona, Validation of analytical methods for pharmaceutical analysis, copyright ©2009, Mourne Training Service, page 12 and page 1 and 73.
9. Panthagada S, Kancherla S, Kandiboti L, Appapurapu AK, Gutta S. Method development and validation of Atenolol in tablet dosage form by RP HPLC method. *Int Res J Pharmacy*, ISSN 2230-8407, 2012. [http://dx.doi.org/10.13040/IJPSR.0975-8232.8\(6\).1000-10](http://dx.doi.org/10.13040/IJPSR.0975-8232.8(6).1000-10)
10. UK Prospective diabetes study group, efficiency of atenolol and captopril in reducing risk of macro vascular and micro vascular complication in type 2 diabetes :UK PDS 39.*PMJ* 1998;317:713-20. **PMID: 9732338**
11. Abdussleem K. Analytical method development and validation of losartan potassium and Atenolol in combined dosage form by RP- HPLC. *Int J Pharma Tech Res CODEN USA* 2010; 2(1):471-474.